title: Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy.
abstract: It has been reported that circulating matrix metalloproteinase (MMP) levels are upregulated in patients with chronic heart failure. However, experimental studies indicate that differences in the profiles of MMPs and tissue inhibitors of metalloproteinase (TIMPs) may exist in ischemic compared with nonischemic cardiomyopathy. This study examined whether circulating levels of MMPs and TIMP-1 are related to the pathogenesis of heart failure. Circulating levels of MMP-2, MMP-3, and TIMP-1 were assessed in 52 patients with compensated end-stage chronic heart failure, including 26 patients (mean 64 +/- 7 years; 10 men) with ischemic cardiomyopathy (IC) and 26 (mean age 66 +/- 6 years; 14 men) with idiopathic dilated cardiomyopathy (IDC). Serum MMP-2 (p <0.001) and MMP-3 (p <0.001) levels were higher in patients with IDC than in those with IC. Serum TIMP-1 levels were lower in patients with IDC (p = 0.011) than in those with IC. This study shows that in patients with compensated end-stage chronic heart failure, circulating levels of MMP-2, MMP-3, and TIMP-1 are associated with the pathogenesis of heart failure.
authors.affiliation: University Cardiology Department, Democritus University of Thrace, Alexandroupolis, Greece. dtziakas@hotmail.com
authors.forename: Dimitrios N
authors.initials: DN
authors.lastname: Tziakas
authors.forename: Georgios K
authors.initials: GK
authors.lastname: Chalikias
authors.forename: Miltiadis
authors.initials: M
authors.lastname: Papaioakeim
authors.forename: Eleni I
authors.initials: EI
authors.lastname: Hatzinikolaou
authors.forename: Dimitrios A
authors.initials: DA
authors.lastname: Stakos
authors.forename: Ioannis K
authors.initials: IK
authors.lastname: Tentes
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papanas
authors.forename: Alexandros
authors.initials: A
authors.lastname: Kortsaris
authors.forename: Efstratios
authors.initials: E
authors.lastname: Maltezos
authors.forename: Dimitrios I
authors.initials: DI
authors.lastname: Hatseras
mesh_terms: D000368:Aged; D002311:Cardiomyopathy, Dilated / Q000097:blood* / Q000503:physiopathology; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000503:physiopathology; D006352:Heart Ventricles / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D019278:Matrix Metalloproteinase 3 / Q000097:blood*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood* / Q000503:physiopathology; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood; D020257:Ventricular Remodeling / Q000502:physiology
chemical_list: D019715:Tissue Inhibitor of Metalloproteinase-1; D019278:Matrix Metalloproteinase 3; D020778:Matrix Metalloproteinase 2